190 likes | 345 Views
MicroFlow NMR. Advances in NMR Automation for 2006. Sensitivity. Simplicity. Economy. Why MicroFlow?. Make less, use less, dispose of less BETTER ECONOMICS! Miniaturized RF Design HIGHER MASS SENSITIVITY! Easier to shim and install SIMPLICITY!
E N D
MicroFlow NMR Advances in NMR Automation for 2006
Sensitivity Simplicity Economy Why MicroFlow? • Make less, use less, dispose of less BETTER ECONOMICS! • Miniaturized RF Design HIGHER MASS SENSITIVITY! • Easier to shim and install SIMPLICITY! • Utilizes modern sample formats => VERSITILITY! • Enhanced signal-to-solvent ratio INFORMATION QUALITY! • Excellent salt tolerance LESS SAMPLE-TO-SAMPLE VARIATIONS! • Excellent fluidics PRESERVE SAMPLE CONCENTRATION! • Uni-directional flow MAXIMIZE SPEED, MINIMIZE CARRY-OVER! • Fused silica/FEP pathways EXCELLENT SOLVENT COMPATIBILITY! • Diverse range of sample management options MAXIMIZE YOUR MAGNET AND SPECTROMETER INVESTMENT! • Compatible with Varian, Bruker, JEOL, Waters, and other NMR and fluidic platforms
Great Sensitivity, Easy Operation, Excellent Spectral Quality
CapNMR Performance Get an independent assessment of performance from a major NMR vendor who has used our probe - Download 30-page specifications document at www.jeolusa.com/nmr/nmrprods/cap_probe.html Data Courtesy of Mike Frey, JEOL USA, Peabody, MA USA
NMR Product Positions Precious Sample Analysis Turnkey Solutions Gronquist et al., JACS 2005, 127, 10810 Jansma et al., Anal. Chem. 2005, 77, 6509
Precious Sample Analysis PositionDirect Injection Easy, Effective, Efficient Sample is easily dispensed from syringe to probe Sample Vials Simple Plumbing To learn more about Direction Injection Loading, see the Protasis/MRM Technical Bulletin G0020 in the Tech Support Knowledge Base at www.microNMR.com
Precious Sample AnalysisFirefly Steriods Spectral analysis allowed for complete structural characterization of all three major components, compounds 1, 8, and 13. dqf-COSY HMQC HMBC NOESY M. Gronquist et al., JACS 2005, 127, pp. 10810-10811
Precious Sample AnalysisNatural Products Dereplication ~ 5 µg/well 250 µg HPLC Courtesy John Blunt, U. Canterbury, and Kirk Gustafson, NCI (see March 2006 Gordon Conf. On Natural Products Presentations at www.microNMR.com)
Precious Sample AnalysisAssisted Direct Injection • Semi-automated • Calibrated Delivery Volume • “Push-Button” Operation • Pressure Sensing To learn more about Assisted Direct Injection, see the Protasis/MRM HTSL Technical Notes in the Manuals section of the Tech Support Knowledge Base at www.microNMR.com
Precious Sample AnalysisAssisted Direct Injection Micro-SPE of Metabolites Courtesy Andreas Kaerner, Eli Lilly, ENC 2004
Standard sample formats • Sensitivity • Capacity • Integration/functionality • Automation • Decision-making • Multi-solvent/open access • Easy to Use # of Samples $/Sample Turnkey Solutions IN OUT Modern sample input format Decision-making SW Web-based GUI control Secure Data Server
Thermal Control Wash Station Protasis One Minute NMR Control/automation SW Injector option: return-to-vial or well Port-in-Valve Injection! Minimal sample dilution, minimal dead volume
Sample QueueAutomation Open-AccessWeb Interface Solvent Management One-Minute NMRTMTurnkey Solutions for NMR Liquid Handling1 Sensitive CapNMRProbe NMR Instrument Control2 ACD/Labs Processing and Databasing3 E-mail and Web Reporting 1 Leap/CTC2 Varian or Bruker3 ACD/Labs Productivity
Protasis One Minute NMRBruker DPX-400, 10µL Sample Volume in Well, 5µL Injection 1) Med. Chem. Support/ Library QC • 384-well plates 2) Walk-up Med. Chem. Analysis • Microvials Courtesy Bernhard Geierstanger GNF
Protasis One Minute NMRHuman Serum with High Throughput CapNMR Serum Carryover Studies Single rinse protocols, in combination with injection port maintenance, reduce carryover to negligible values, well less than 1% Urine
Sensitivity Simplicity Economy 600MHz capillary NMR, ns,64 10 g/10 L Protasis Corporation For More Information, Visit: www.protasis.com (product offering) www.microNMR.com (technical support) Graphics on this page complements of: • Mark O’Neil-Johnson, Sequoia Sciences • Wolfgang Peti, Brown University • Brad Bendiak, U. Colorado Health Sciences Center • Dave Detlefsen, Novatia • Jane Strouse, UCLA • Kirk Gustafson, NCI and John Blunt, U. Canterbury Protasis technology has been advanced though the support of: NIH RR14392, RR11755, HL56546, RR14661, RR16387, EB001626-01, RR15384, RR020239, NSF DMI-9523220